Wilkinson GR - Search Results

1

Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.

Kaisary A, Smith P, Jaczq E, McAllister CB, Wilkinson GR, Ray WA, Branch RA. Kaisary A, et al. Among authors: wilkinson gr. Cancer Res. 1987 Oct 15;47(20):5488-93. Cancer Res. 1987. PMID: 3652049

2

Genetic polymorphism of S-mephenytoin hydroxylation.

Wilkinson GR, Guengerich FP, Branch RA. Wilkinson GR, et al. Pharmacol Ther. 1989;43(1):53-76. doi: 10.1016/0163-7258(89)90047-8. Pharmacol Ther. 1989. PMID: 2675129 Review. No abstract available.

3

Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.

Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Ward SA, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 1989 Jan;45(1):72-9. doi: 10.1038/clpt.1989.11. Clin Pharmacol Ther. 1989. PMID: 2910639

4

Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer.

Fleming CM, Persad R, Kaisary A, Smith P, Adedoyin A, Porter J, Wilkinson GR, Branch RA. Fleming CM, et al. Among authors: wilkinson gr. Pharmacogenetics. 1994 Aug;4(4):199-207. doi: 10.1097/00008571-199408000-00004. Pharmacogenetics. 1994. PMID: 7987404

5

Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population.

May DG, Porter J, Wilkinson GR, Branch RA. May DG, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 1994 May;55(5):492-500. doi: 10.1038/clpt.1994.62. Clin Pharmacol Ther. 1994. PMID: 8181193 Free article.

6

The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer.

Fleming CM, Kaisary A, Wilkinson GR, Smith P, Branch RA. Fleming CM, et al. Among authors: wilkinson gr. Pharmacogenetics. 1992 Jun;2(3):128-34. doi: 10.1097/00008571-199206000-00004. Pharmacogenetics. 1992. PMID: 1306112

7

Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease.

Black C, May G, Csuka ME, Lupoli S, Wilkinson GR, Branch RA. Black C, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 1992 Dec;52(6):659-67. doi: 10.1038/clpt.1992.204. Clin Pharmacol Ther. 1992. PMID: 1458774

8

The disposition of dapsone in cirrhosis.

May DG, Arns PA, Richards WO, Porter J, Ryder D, Fleming CM, Wilkinson GR, Branch RA. May DG, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 1992 Jun;51(6):689-700. doi: 10.1038/clpt.1992.81. Clin Pharmacol Ther. 1992. PMID: 1611807

9

The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects.

May DG, Porter JA, Uetrecht JP, Wilkinson GR, Branch RA. May DG, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 1990 Dec;48(6):619-27. doi: 10.1038/clpt.1990.204. Clin Pharmacol Ther. 1990. PMID: 2249373

10

Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin.

May DG, Black CM, Olsen NJ, Csuka ME, Tanner SB, Bellino L, Porter JA, Wilkinson GR, Branch RA. May DG, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 1990 Sep;48(3):286-95. doi: 10.1038/clpt.1990.151. Clin Pharmacol Ther. 1990. PMID: 2401127

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

239 results

Search Page

Filters